By Stephanie Nebehay GENEVA (Reuters) -The World Health Organization (WHO) and other aid groups on Thursday appealed to leaders of the world's 20 biggest economies to fund a $23.4...
By Dhirendra TripathiInvesting.com – Merck stock (NYSE:MRK) gained more than 4% Thursday as the drug maker raised its annual forecast after its earnings shot past estimates...
By Michael Erman and Manas Mishra (Reuters) -Merck & Co Inc on Thursday said its experimental COVID-19 drug could bring in between $5 billion and $7 billion in sales through the...
Acceleron Pharma (XLRN)'s assets could be added to the cardiovascular portfolio and pipeline of Merck & Co. (MRK) soon. The U.S. drug giant is attempting to acquire approximately...
Merck (MRK) is one of the largest international healthcare companies, focusing on delivering innovative health solutions through its prescription medicines, vaccines, biologic...
Merck To Double Production Of 'Breakthrough' COVID Drug As Nations Line Up To BuyDespite safety concerns raised by multiple scientists, Merck is signing deals with countries left...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 269.60 | 273.60 | 269.60 | -1.95 | -0.72% | 13.56M | London | |||
| 108.98 | 111.78 | 108.98 | -3.04 | -2.71% | 75.90M | London | |||
| 49.58 | 50.33 | 49.15 | +0.62 | +1.27% | 193.63M | London | |||
| 210.50 | 233.50 | 203.50 | -17.00 | -7.47% | 2.18M | London | |||
| 21.18 | 21.88 | 21.14 | -0.64 | -2.93% | 322.18K | London | |||
| 39.00 | 39.00 | 39.00 | -0.50 | -1.27% | 23.49K | London | |||
| 1,553.50 | 1,584.00 | 1,552.00 | -29.00 | -1.83% | 888.69K | London | |||
| 229.00 | 230.50 | 228.50 | 0.00 | 0.00% | 0.00 | London | |||
| 1,499.00 | 1,506.60 | 1,459.20 | +57.20 | +3.97% | 11.33M | London | |||
| 685.50 | 687.00 | 671.50 | +12.50 | +1.86% | 2.65M | London | |||
| 200.25 | 200.25 | 200.25 | +1.50 | +0.75% | 126.34K | London | |||
| 256.60 | 263.80 | 249.60 | -4.00 | -1.53% | 1.02M | London | |||
| 17.40 | 17.60 | 17.10 | +0.030 | +0.17% | 31.72M | London | |||
| 1,700.00 | 1,702.00 | 1,700.00 | 0.00 | 0.00% | 0.00 | London | |||
| 10.25 | 10.80 | 10.80 | -0.50 | -4.65% | 1.42M | London |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women’s health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.